Regional cerebral THK5351 accumulations correlate with neuropsychological test scores in Alzheimer continuum

Document Type : Original Article

Authors

1 Department of Radiology, Kindai University Faculty of Medicine, Osakasayama, Osaka, Japan

2 Institute of Advanced Clinical Medicine, Kindai University Faculty of Medicine, Osakasayama, Osaka, Japan

Abstract

Objective(s): We evaluated the relationship between regional accumulations of the tau positron emission tomography (PET) tracer THK5351 and cognitive dysfunction in the Alzheimer's disease (AD) continuum.
Methods: The cases of 18 patients with AD or mild cognitive impairment (MCI) due to AD who underwent three-dimensional MRI, fluoro-2-deoxyglucose (FDG)-(PET), Pittsburgh compound B (PiB)-amyloid PET, and THK5351-tau PET were analyzed. Their mean age was 70.6±11.3, their mean Mini-Mental State Examination (MMSE) score was 22.3±6.8, and their mean Alzheimer Disease Assessment Scale-Cognitive Subtest (ADAS) score was 12.5±7.3. To determine the correlation between each patient's four imaging results and their MMSE and ADAS scores, we performed a voxel-wise statistical analysis with statistical parametric mapping (SPM).
Results: The SPM analysis showed that the bilateral parietotemporal FDG accumulations and MMSE scores were positively correlated, and the bilateral parietotemporal FDG accumulations were negatively correlated with ADAS scores. There were significant correlations between bilateral parietotemporal and left posterior cingulate/precuneus THK5351 accumulations and MMSE/ADAS scores.
Conclusion: In the AD brain, THK5351 correlates with neuropsychological test scores as well as or more additional than FDG due to its affinity for both tau and monoamine oxidase-B (MAO-B), and measurements of THK5351 may thus be useful in estimating the progression of AD.

Keywords

Main Subjects

References

  1. Jack Jr CR, Albert MS, Knopman DS, McKhann GM, Sperling RA, Carrillo MC, Thies B, Phelps CH. Introduction to the recommendations from the National Institute on Aging-Alzheimer's Association workgroups on diagnostic guidelines for Alzheimer's disease. Alzheimer's & dementia. 2011; 7(3):257-62.
  2. Jack Jr CR, Bennett DA, Blennow K, Carrillo MC, Dunn B, Haeberlein SB, Holtzman DM, Jagust W, Jessen F, Karlawish J, Liu E. NIA-AA research framework: toward a biological definition of Alzheimer's disease. Alzheimer's & Dementia. 2018; 14(4):535-62.
  3. Knopman DS, Haeberlein SB, Carrillo MC, Hendrix JA, Kerchner G, Margolin R, Maruff P, Miller DS, Tong G, Tome MB, Murray ME. The National Institute on Aging and the Alzheimer's Association research framework for Alzheimer's disease: perspectives from the research roundtable. Alzheimer's & Dementia. 2018; 14(4):563-75.
  4. Devous MD, Sr., Fleisher AS, Pontecorvo MJ, Lu M, Siderowf A, Navitsky M, et al. Relationships Between Cognition and Neuropathological Tau in Alzheimer's Disease Assessed by 18F Flortaucipir PET. J Alzheimers Dis. 2021; 80:1091-104.
  5. McKhann GM, Knopman DS, Chertkow H, Hyman BT, Jack CR, Jr., Kawas CH, et al. The diagnosis of dementia due to Alzheimer's disease: recommendations from the National Institute on Aging-Alzheimer's Association workgroups on diagnostic guidelines for Alzheimer's disease. Alzheimers 2011; 7:263-9.
  6. Albert MS, DeKosky ST, Dickson D, Dubois B, Feldman HH, Fox NC, et al. The diagnosis of mild cognitive impairment due to Alzheimer's disease: recommendations from the National Institute on Aging-Alzheimer's Association workgroups on diagnostic guidelines for Alzheimer's disease. Alzheimers Dement. 2011; 7:270-9.
  7. Mathis CA, Wang Y, Holt DP, Huang GF, Debnath ML, Klunk WE. Synthesis and evaluation of 11C-labeled 6-substituted 2-arylbenzothiazoles as amyloid imaging agents. J Med Chem. 2003; 46:2740-54.
  8. Hosokawa C, Ishii K, Hyodo T, Sakaguchi K, Usami K, Shimamoto K, et al. Investigation of (11)C-PiB equivocal PET findings. Ann Nucl Med. 2015; 29:164-9.
  9. Harada R, Okamura N, Furumoto S, Furukawa K, Ishiki A, Tomita N, et al. 18F-THK5351: A Novel PET Radiotracer for Imaging Neurofibrillary Pathology in Alzheimer Disease. J Nucl Med. 2016; 57:208-14.
  10. Hirayama A, Yamada T, Ishii K. Comparison with regional glucose metabolism, amyloid deposition and tau deposition between dementia with Lewy bodies and Alzheimer disease brains. Acta Medica Kindai University. 2022; 47: 11-16.
  11. Ishii K, Yamada T, Hanaoka K, Kaida H, Miyazaki K, Ueda M, et al. Regional gray matter-dedicated SUVR with 3D-MRI detects positive amyloid deposits in equivocal amyloid PET images. Ann Nucl Med. 2020; 34:856-63.
  12. Akamatsu G, Ikari Y, Ohnishi A, Nishida H, Aita K, Sasaki M, et al. Automated PET-only quantification of amyloid deposition with adaptive template and empirically pre-defined ROI. Phys Med Biol. 2016; 61:5768-80.
  13. Scheltens P, Leys D, Barkhof F, Huglo D, Weinstein HC, Vermersch P, et al. Atrophy of medial temporal lobes on MRI in "probable" Alzheimer's disease and normal ageing: diagnostic value and neuro-psychological correlates. J Neurol Neurosurg Psychiatry. 1992; 55:967-72.
  14. Sperling RA, Aisen PS, Beckett LA, Bennett DA, Craft S, Fagan AM, et al. Toward defining the preclinical stages of Alzheimer's disease: recommendations from the National Institute on Aging-Alzheimer's Association workgroups on diagnostic guidelines for Alzheimer's Alzheimers Dement. 2011; 7:280-92.
  15. Thientunyakit T, Thongpraparn T, Sethanandha C, Yamada T, Kimura Y, Muangpaisan W, et al. Relationship between F-18 florbetapir uptake in occipital lobe and neurocognitive performance in Alzheimer's disease. Jpn J Radiol. 2021; 39:984-93.
  16. Qiao Z, Wang G, Zhao X, Wang K, Fan D, Chen Q, et al. Neuropsychological Performance Is Correlated With Tau Protein Deposition and Glucose Metabolism in Patients With Alzheimer's Disease. Front Aging Neurosci. 2022; 14:841942.
  17. Nobili F, Mazzei D, Dessi B, Morbelli S, Brugnolo A, Barbieri P, et al. Unawareness of memory deficit in amnestic MCI: FDG-PET findings. J Alzheimers Dis. 2010; 22:993-1003.
  18. Harada R, Ishiki A, Kai H, Sato N, Furukawa K, Furumoto S, et al. Correlations of (18)F-THK5351 PET with Postmortem Burden of Tau and Astrogliosis in Alzheimer Disease. J Nucl Med. 2018; 59:671-4.
  19. Carter SF, Herholz K, Rosa-Neto P, Pellerin L, Nordberg A, Zimmer ER. Astrocyte Biomarkers in Alzheimer's disease. Trends Mol Med. 2019; 25:77-95.
  20. Ishii K. PET approaches for diagnosis of dementia. AJNR Am J Neuroradiol. 2014; 35:2030-8.
  21. Matsuda H, Shigemoto Y, Sato N. Neuro imaging of Alzheimer's disease: focus on amyloid and tau PET. Jpn J Radiol. 2019; 37:735-49.
  22. Sintini I, Schwarz CG, Martin PR, Graff-Radford J, Machulda MM, Senjem ML, et al. Regional multimodal relationships between tau, hypometabolism, atrophy, and fractional anisotropy in atypical Alzheimer's disease. Hum Brain Mapp. 2019; 40:1618-31.
Asia Oceania Journal of Nuclear Medicine and Biology
Volume 11, Issue 1
January 2023
Pages 37-43

Files

Share

How to cite

Statistics